Better Cancer Diagnostic and Prognostic Testing

for Better Outcomes

Founded in 2022 by Dr. Richard Pestell, StromaGenesis, LLC is a clinical-stage biotechnology company that focuses on tumor microenvironment biology, combining diagnostic precision with therapeutic potential.

Leveraging assets that are the product of over 18 years of academic work to develop:

  • Proprietary algorithm for a more precise prostate cancer prognosis

  • Tissue-based immunoassay to predict therapy response in multiple solid tumors (breast, colon, prostate, glioblastoma, etc.), and;

  • Tissue-based and blood-based immunoassay as companion diagnostic test for multiple solid tumors

Richard Pestell

AO., MD., PhD, MBA, Founder & CEO

  • Relevant start-up experience: founded/funded ProstaGene, LightSeed, EcoGenome (and sold ProstaGene, 2018)

  • Inventor of 30 Patents

  • Director of two NCI Cancer Centers (2002-2016)

  • Director Lombardi Comprehensive Cancer Center

    Georgetown University

  • Director Sidney Kimmel Comprehensive Cancer Center

    Thomas Jefferson University

    Oversaw > 120 clinical trials (phase 1, 2, 3)

    Established Phase 1 program

    Current examiner of NCI designated Cancer Centers

  • Chairman, Department of Oncology, Georgetown University (2002)

  • Executive Vice President Thomas Jefferson University (2014)

  • Annual budget of $5.6B, eleven hospitals | 30,000 employees

  • World Ranked Oncology Research

  • Google Scholar (#1 cell cycle, #5 prostate, #13 breast cancer)

  • 600 papers, > 110,000 citations, H index 162

  • Advisor | Reviewer for NCI Cancer Centers | MD Anderson Breast Cancer

  • Award and Honors (Wikipedia)

StromaGenesis Team

Stephen Hull

Reimbursement Consultant

Principal at Covance, Sr. Vice President for Global Reimbursement at AdvaMed, President & Founder of Hull Associates LLC, (global reimbursement strategy firm focused on pharmaceutical, medical device, diagnostic & biotech technologies) (Boston, MA) now Avania

Dr. Alberto Guitirez

Regulatory Consultant

Director of the FDA’s Office of In Vitro Diagnostics and Radiological Health from 2009-2017, Gutierrez guides regulatory strategy, device approvals, and compliance for in vitro diagnostics and radiological devices, advising biopharma and medical device clients through NDA Partners.

Kevin Ellison

Consultant

Head of Business Development for North America at Almac Diagnostic Services, Ellison supports biomarker discovery and companion diagnostics, builds key partnerships, and guides biopharma teams in using diagnostic solutions, assay design, & lab data across global clinical programs.

Dr. Hallgeir Rui MD, PhD

Consultant

Professor of Pharmacology, Physiology & Cancer Biology Thomas Jefferson University

Director of the Pathology Translational Research Shared Resource at Sidney Kimmel Comprehensive Cancer Center, Rui leads a lab in molecular profiling and resistance in HR-positive breast cancer.

Andrew Kossenkov, PhD

Bioinformatics Consultant

Assistant Professor at the Vaccine & Immunotherapy Center, Kossenkov applies computational approaches to biomedical high-throughput data analysis, interpreting results and visualizing complex data, following his training in computer science, bioinformatics & biomedical science at multiple institutes in Philadelphia.

Professor X. Jiao

Consultant

Associate Professor at the Baruch S. Blumberg Institute, Instructor in Cancer Biology at Sidney Kimmel Cancer Center, Thomas Jefferson University, from 2005-2016, Jiao studies CCR5 antagonists, tumor suppressors, & oncogenes to block tumor metastasis and stem cell growth.

Professor Z. Li

Consultant

Associate Professor at the Baruch S. Blumberg Institute, Li researches tumor development in breast & prostate cancer, including DACH1 regulation, DNA repair, cyclin D1, & BCL6 pathways, & her work informs molecular mechanisms & therapy strategies in cancer research.

StromaGenesis Advisory Board

Recognized Industry Leaders

Dr. Fernando Rubio, PhD

  • Chief Executive Officer, Eurofins Abraxis L.L.C. | https://www.eurofins.com/contact-us/worldwide-interactive-map/usa/eurofins-abraxis/

  • Founder Abraxis, Clinical diagnostics (genetics), manufacturing and distribution company. >110 million tests per year

  • Eurofins clinical diagnostics laboratories offer testing services in all medical specialties, from routine testing to esoteric testing including advanced and often proprietary genetic testing solutions. (now Gold Standards Diagnostic

Dr. Thomas Errico, MD

  • Board-certified orthopedic surgeon since 1986 & pediatric spine surgeon at Nicklaus Children’s Hospital

  • Founder of K2M Group Holdings, Inc.

  • Co-Founder of Electrocore and SpineCore

  • Chief of Spine Surgery at NYU Langone from 1998-2018

  • Errico specializes in spinal surgery

Dr. Denis Burger, PhD

  • Developed and brought 4 companies to NASDAQ

  • Trinity Biotech Co-founder and Chairman

  • Previous Vice Chairman of CytoDyn Inc. Chairman and Chief Executive Officer of AVI Biopharma Inc, non-executive director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company, and co-founder and Chairman of Epitope Inc

Dr. Hallgeir Rui, MD, PhD

  • Professor of Pharmacology & Cancer Biology, Thomas Jefferson University

  • Director, Translational Pathology Core, Sidney Kimmel Cancer Center

General inquiries:

[email protected]

100 East Lancaster Ave

Room R234

Wynnewood, Pennsylvania 19096

© 2025 StromaGenesis. All rights reserved.

Privacy Policy